<DOC>
	<DOCNO>NCT00634049</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety isavuconazole treatment renally impaired participant invasive fungal infection cause Aspergillus participant invasive fungal disease cause rare fungi .</brief_summary>
	<brief_title>Isavuconazole Treatment Renally Impaired Aspergillosis Rare Fungi</brief_title>
	<detailed_description>Acute invasive fungal infection cause aspergillus , rare mould , yeast dimorphic fungi life threaten disease . Early treatment highly effective anti-fungals reduces mortality . This study investigate safety efficacy isavuconazole participant aspergillosis renal impairment , participant suffer invasive infection rare fungi .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Aspergillosis</mesh_term>
	<criteria>•Participants meet EORTC/MSG ( European Organization Research Treatment Cancer/Mycoses Study Group ) definition proven culture positive probable IFD ( invasive fungal disease ) cause rare mould , yeast , dimorphic fungi ( i.e . fungal pathogen Aspergillus fumigatus Candida specie ) whether renally impair ( include dialysis ) require primary therapy IFD time enrollment . OR •Participants proven probable zygomycosis , whether renally impair ( include dialysis ) , require primary therapy . Zygomycosis must document culture histology / cytology . OR •Participants meet EORTC/MSG definition proven culture positive probable IFD cause rare mould , yeast , dimorphic fungi ( i.e. , fungal pathogen Aspergillus fumigatus Candida specie ) , whether RI ( include dialysis ) , refractory current treatment define , Clear documentation progression disease . Note : radiological progression association white blood cell ( WBC ) count recovery acceptable . Failure improve clinically despite receive least 7 day standard antifungal regimen . Prior enrol patient fell category , Medical Monitor contact approval . OR • Participants meet EORTC/MSG definition proven culture positive probable IFD cause rare mould , yeast , dimorphic fungi ( i.e. , fungal pathogen Aspergillus fumigatus Candida specie ) , whether RI ( include dialysis ) , intolerant current treatment example : Doubling serum creatinine value high upper limit normal ( ULN ) within 48 hour . Serum creatinine &gt; 2.0 mg/mL current treatment polyene IV voriconazole . Other significant drugrelated adverse reaction ( ) current antifungal agent , result discontinuation treatment , e.g. , persistence visual disturbance , allergic reaction , phototoxicity severe infusion reaction ( hypertensive crisis , severe chill shock ) . Documented inability achieve adequate blood level posaconazole , voriconazole itraconazole . A known condition participant may jeopardize adherence protocol requirement Participants unlikely survive 30 day Participants body weight &lt; 40 kg Women pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>invasive fungal infection cause rare mold , rare yeast</keyword>
	<keyword>BAL8557</keyword>
	<keyword>Isavuconazole</keyword>
	<keyword>Aspergillosis</keyword>
	<keyword>dimorphic fungi</keyword>
	<keyword>ASP9766</keyword>
</DOC>